senior medical correspondent elizabeth cohen joins us now. how promising is this new drug? and given the side effects, is it worth it in terms of what researchers are saying at this point? bianna, essentially that s what the u.s. food & drug administration has to decide. they fasttracked this drug, but the study authors themselves say that longer studies need to be done. so efficacy, first, what they did, they took 1800 people between the ages of 50 and 90 who had mild early stages of alzheimer s. hat goff a ploo seo, hat the dripping. the half that got the drug did see a decline, but 27% slower. also, the folks in the drug group they lower levels of amyloid.
when they were given a dose of it their depression symptoms really did go down when they were given the highest dose and it worked quite quickly. much more quickly than antide antidepressants. after 12 weeks that response was not sustained. so there seems to be an issue with how long this lasts and in addition 77% of the study participates had side effects like headaches and nausea and dizziness so it s important to note this could maybe in the future be a possibility for folks where other kinds of therapies don t work to treat their depression, but the study authors noted that there was a concern about some of the folks who took these drug, a number of them thought about suicide, in addition a number of them ended up going back on their antidepressants so this isn t perfect. it may be magic mushrooms but it s not a magic cure, kate. interesting. very interesting. really appreciate it, elizabeth. so, if you want a shot at
Frankfurt am Main (ots) - - Die Folgen der Pandemie sind weitestgehend überwunden und der europäische Bankenmarkt befindet sich im Aufschwung. Die Transformationsprogramme für mehr Effizienz sowie Anpassungen